Search
Ibalizumab
go.drugbank.com/drugs/DB12698ApprovedInvestigationalIn October 2022, the FDA approved the administration of Trogarzo (ibalizumab-uiyk) by intravenous push, allowing for a faster drug administration.[L43443,L43448] … It is an advanced and current antibody in development for the treatment of HIV/AIDS. It has been developed by Taimed biologics and Theratechnologies [L1558, L1554].
Categories: HIV 1 Post-attachment Fusion Inhibitors, Human Immunodeficiency Virus 1 Post-attachment Fusion InhibitorEucalyptol
go.drugbank.com/drugs/DB03852ApprovedInvestigationalNutraceuticalIt kills leukaemia cells in vitro. … Eucalyptol is naturally produced cyclic ether and monoterpenoid. Eucalyptol is an ingredient in many brands of mouthwash and cough suppressant.
Mixtures: Demo Cineol Inj, UNGÜENTO TIBET ®Categories: Compounds used in a research, industrial, or household settingAnagrelide
go.drugbank.com/drugs/DB00261ApprovedInvestigational[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. … Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.
Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesProducts: ANAGRELID RATIO 1 MG, Anagrelid Nordic 1 mg TablettenFluoxetine
go.drugbank.com/drugs/DB00472ApprovedInvestigationalVet approvedFluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). … [A181673] It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies
Synonyms: (+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine, (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamineInternational brands: Animex-OnAtrasentan
go.drugbank.com/drugs/DB06199ApprovedInvestigational[L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist … Atrasentan is a novel, selective endothelin A receptor antagonist (SERA).
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitorsPralsetinib
go.drugbank.com/drugs/DB15822ApprovedInvestigationalIt is currently marketed under the brand name GAVRETO™ by Blueprint Medicines.[L15986] … [A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsMiglustat
go.drugbank.com/drugs/DB00419ApprovedInvestigationalHowever, clinical experience with miglustat showed that therapeutic levels of the drug could not be achieved in patients without a high incidence of adverse effect. … Miglustat was first developed as an anti-HIV agent in the 1990s.
Synonyms: N-(n-Butyl)deoxynojirimycin, N-butyl-1-deoxynojirimycinCategories: Heterocyclic Compounds, 1-RingIslatravir
go.drugbank.com/drugs/DB15653ApprovedInvestigationalIslatravir is a first-in-class, highly potent nucleoside reverse transcriptase translocation inhibitor (NRTTI) used in combination therapy for the treatment of HIV-1 infection. … [A275492, L56138] Chemically, it is a deoxyadenosine analogue distinguished by a 4'-ethynyl group and a 2-fluoro substitution, which collectively enhance its metabolic stability and potency.
Categories: Heterocyclic Compounds, 2-RingSynonyms: 4'-ethynyl-2-fluoro-2'-deoxyadenosineNabilone
go.drugbank.com/drugs/DB00486ApprovedInvestigationalit is considered to be twice as active as Δ⁹-THC. … Though it was approved by the FDA in 1985, the drug only began marketing in the United States in 2006. It is also approved for use in treatment of anorexia and weight loss in patients with AIDS.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsProducts: Canemes 1 mg KapselnRaloxifene
go.drugbank.com/drugs/DB00481ApprovedInvestigational[A4977] Available in many countries worldwide, raloxifene was initially approved by the FDA in December, 1997 under the market name Evista® for the management and prevention of osteoporosis in postmenopausal … However, it has a negligible effect on altering the development and progression of breast cancer itself.
Synonyms: (2-(4-Hydroxyphenyl)-6-hydroxybenzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanoneCategories: P-glycoprotein substrates, Cytochrome P-450 CYP2B6 Inhibitors